| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HED.25440 |
| P698 | PubMed publication ID | 30552828 |
| P50 | author | Malte Kriegs | Q90183351 |
| Kai Rothkamm | Q39034555 | ||
| P2093 | author name string | Cordula Petersen | |
| Simon Laban | |||
| Nikolaus Möckelmann | |||
| Adrian Münscher | |||
| Konstantin Hoffer | |||
| Lisa Gleißner | |||
| Leonhard Steinmeister | |||
| Lara Bußmann | |||
| Anh Thu Vu | |||
| Kaweh Beizaei | |||
| P2860 | cites work | Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation | Q40408804 |
| Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells | Q41133695 | ||
| Radiosensitization of brain metastasis by targeting c-MET. | Q44392303 | ||
| Analyzing the influence of kinase inhibitors on DNA repair by differential proteomics of chromatin-interacting proteins and nuclear phospho-proteins. | Q49621266 | ||
| Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. | Q52581305 | ||
| Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) | Q27671432 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation | Q28545198 | ||
| Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. | Q33990908 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis | Q34482745 | ||
| Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression | Q35221521 | ||
| CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice | Q35528287 | ||
| A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. | Q35693308 | ||
| Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development | Q36107937 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Biology of interactions: antiepidermal growth factor receptor agents | Q36935078 | ||
| MET signalling: principles and functions in development, organ regeneration and cancer | Q37811895 | ||
| Molecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment | Q38382066 | ||
| c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. | Q38392890 | ||
| HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. | Q38883827 | ||
| The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells | Q38954568 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation | Q39109185 | ||
| Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway | Q39150740 | ||
| Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model | Q39392131 | ||
| Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo | Q39408812 | ||
| Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines | Q39472878 | ||
| Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins | Q39546437 | ||
| Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests | Q39696362 | ||
| P433 | issue | 1 | |
| P921 | main subject | head and neck squamous cell carcinoma | Q18348812 |
| P304 | page(s) | 208-215 | |
| P577 | publication date | 2018-12-15 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC | |
| P478 | volume | 41 |
| Q92531037 | Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients | cites work | P2860 |
Search more.